Ocugen Stock

Ocugen EBIT per Employee

The EBIT per Employee of Ocugen (OCGN) as of Aug 17, 2026 is -3.97 M USD. In the previous year, EBIT per Employee was -3.42 M USD — a change of 16.11% (lower).

EBIT per Employee

-3.97 MUSD

YoY

16.11%

Last updated:

EBIT per Employee of Ocugen is 2026 -3.97 M USD. EBIT per Employee of Ocugen was 2025 -3.42 M USD. It decreases by 16.11% lower compared to the previous year.
Access this data via the Eulerpool API

Ocugen Stock analysis

What does Ocugen do? Ocugen Inc is a US-based biopharmaceutical company specializing in the development and commercialization of innovative therapeutics and vaccines. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania. It has a strong pipeline of products in various stages of development, with a focus on treating eye diseases and other medical conditions. Ocugen has also entered into partnerships for the development and marketing of COVID-19 vaccines, including Covaxin. Overall, Ocugen Inc is expected to be a significant player in the biopharmaceutical industry in the coming years. Ocugen is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Ocugen stock

EBIT per Employee of Ocugen is -3.97 M USD in 2026.

EBIT per Employee of Ocugen changed from -3.42 M USD to -3.97 M USD, representing a 16.11% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Employee Ocugen since 2006 – with annual values, charts, and detailed analysis.

EBIT per employee measures operating profit per employee, showing how efficiently the workforce generates operating earnings.

EBIT per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT per Employee's Ocugen historically and in real time.

Access this data via the Eulerpool API

Workforce — Ocugen

All Key Metrics — Ocugen